TDC
JAZZ icon

Thompson Davis & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Thompson Davis & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-43
Closed -$6K – 1126
2017
Q1 		$6K Sell
43
-48
-53% -$6.25K 0.01% 846
2016
Q4 		$10K Buy
91
+39
+75% +$4.34K 0.02% 699
2016
Q3 		$6K Buy
52
+21
+68% +$2.83K 0.01% 796
2016
Q2 		$4K Sell
31
-1
-3% -$147 0.01% 827
2016
Q1 		$4K Sell
32
-1
-3% -$124 0.01% 838
2015
Q4 		$5K Hold
33
– – 0.01% 826
2015
Q3 		$4K Buy
33
+4
+14% +$689 0.01% 883
2015
Q2 		$5K Buy
+29
New +$5.21K 0.01% 896
2014
Q4 		– Sell
-53
Closed -$9K – 1208
2014
Q3 		$9K Buy
+53
New +$8.15K 0.01% 727

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Thompson Davis & Co's JAZZ Position: Q2 2017 in Review

Thompson Davis & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2017, closing a stake of 43 shares — an estimated $6K sold.

Thompson Davis & Co first reported a position in JAZZ in Q3 2014 and held it in 9 quarters. The position peaked at $10K in Q4 2016. 319 funds tracked by Wall St. Rank hold JAZZ as of Q2 2017.

  • Thompson Davis & Co reported no remaining Jazz Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 43 Jazz Pharmaceuticals shares in Q2 2017, an estimated $6K.
  • Thompson Davis & Co first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 9 quarters.
  • Thompson Davis & Co's Jazz Pharmaceuticals position peaked at $10K in Q4 2016.
  • 319 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.